U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

View Full Size 

Download

• Full Size JPEG, 3888x2592, 3.3 MB
• Small JPEG, 480x320, 95.2 KB
• Preview JPEG, 144x96, 27.2 KB
• Thumbnail JPEG, 72x48, 21.2 KB